Benzofuran- and furan-2-yl-(phenyl)-3-pyridylmethanols: Synthesis and inhibition of P450 aromatase

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 20, Issue 2, 2005, Pages 135-141

  Saberi, Mohammed R ^a,b   Shah, Kajal ^a   Simons, Claire ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benzofuran 2 yl (phenyl) 3 pyridylmethanols furan 2 yl (phenyl) 3 pyridylmethanol derivatives; Inhibitors; Molecular modelling; P450 aromatase; Proton affinity

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BENZOFURAN 2 YL(2,4 DICHLOROPHENYL) 3 PYRIDYLMETHANOL; BENZOFURAN 2 YL(4 BROMOPHENYL) 3 PYRIDYLMETHANOL; BENZOFURAN 2 YL(4 CHLOROPHENYL) 3 PYRIDYLMETHANOL; BENZOFURAN 2 YL(4 FLUOROPHENYL) 3 PYRIDYLMETHANOL DERIVATIVE; BENZOFURAN 2 YL(4 IODOPHENYL) 3 PYRIDYLMETHANOL; BENZOFURAN 2 YL(4 METHOXYPHENYL) 3 PYRIDYLMETHANOL; BENZOFURAN 2 YL(PHENYL) 3 PYRIDYLMETHANOL DERIVATIVE; BENZOFURAN DERIVATIVE; FURAN 2 YL(4 CHLOROPHENYL) 3 PYRIDYLMETHANOL; FURAN 2 YL(4 METHOXYPHENYL) 3 PYRIDYLMETHANOL; FURAN 2 YL(PHENYL) 3 PYRIDYLMETHANOL DERIVATIVE; FURAN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICROSOME; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AROMATASE; AROMATASE INHIBITORS; BENZOFURANS; ENZYME INHIBITORS; FURANS; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; METHANOL; MICROSOMES; MODELS, CHEMICAL; MODELS, MOLECULAR; PLACENTA; PROTEIN BINDING; PROTONS; SOFTWARE; TEMPERATURE;

EID: 18444411675     PISSN: 14756366     EISSN: None     Source Type: Journal    
DOI: 10.1080/14756360400015256     Document Type: Article

References (24)

1. Smith HJ, Nicholls PJ, Simons C, Le Lain R. Exp Opin Ther Pat 2001;11:789-824.
2. Banting L In: Ellis GP, Luscombe DK, editors. In Progress in Medicinal Chemistry. Amsterdam: Elsevier Science; 1996. Vol. 33, p 147-184.
3. Brodie A In: Sandler M, Smith HJ, editors. In Design of Enzyme Inhibitors as Drugs. Oxford: Oxford University Press; 1994. Vol. 2, p 424-438.
4. Lønning PE. BMJ 2001;323:880-881.
5. Goss PE, Strasser K. J Clin Oncol 2001;19:881-894.
6. Key TJ. Endocr Relat Cancer 1999;6:175-180.
7. Miller WR. Endocr Relat Cancers 1996;3:65-79.
8. Shaw MA, Nicholls PJ, Smith HJ. J Steroid Biochem 1988;31:137-146.
9. De Coster R, Wouters W, Bowden CR, Bossche HV, Bruynseels J, Tuman RW, Vanginkel R, Snoek E, Vanpeer A, Janssen PAJ. J Steroid Biochem Molec Biol 1990;37:335-341.
10. Whomsley R, Fernandez E, Nicholls PJ, Smith HJ, Lombardi P, Pestellini V. J Steroid Biochem Molec Biol 1993;44:675-676.
11. Vinh TK, Yee SW, Kirby AJ, Nicholls PJ, Simons C. Anticancer Drug Design 2001;16:217-225.
12. Vinh TK, Ahmadi M, Lopez Delgado PO, Fernandez Perez S, Walters HM, Smith HJ, Nicholls PJ, Simons C. Bioorg Med Chem Lett 1999;9:2105-2108.
13. Bisagni AF, J Chem Soc 1955;:3603.
14. Fayed S, Delmas M, Gaset A. Synth Commun 1982;12:1121-1126.
15. Gilman H, Rowe LW, Dickey JB. Rec Trav Chim Pays-Bas 1933;52:395-398.
16. Thompson WA, Siiteri PK. J Biol Chem 1974;249: 5364-5372.
17. http://www.epinions.com/Computer_Associates_International_Inc_CA- Cricket_Graph_III_S0099584
18. http://www.gaussian.com/
19. Foresman JB, Frisch A. Exploring Chemistry With Electronic Structure Methods. 2nd ed. Pittsburgh USA: Inc. Gaussian, 1996.
20. Khodarahmi GA, Smith HJ, Nicholls PJ, Ahmadi M. J Pharm Pharmacol 1998;50(Supplement),207.
21. Laughton CA, Zvelebil MJ, Neidle S. J Steroid Biochem Mol Biol 1993;44:399-407.
22. Guex N, Peirsch M, Torsten S. Diemand A. (2001) Swiss-Pdb Viewer. 3.7th ed. GlaxoSmithKline. http://ca.expasy.org/spdbv/
23. Hasemann CA, Ravichandran KG, Peterson JA. Deisenhofer J, J Mol Biol 1994;236:1169-1185.
24. Khodarahmi GA, Laughton CA, Smith HJ, Nicholls PJ. J Enz Inhib 2001;16:401-416.